HRT Over 70: Benefits, Risks & What You Need to Know

Dr. Shweta Patel, MD, FACOG

Board-certified OB/GYN • U.S. Navy veteran (13 years) • Author, The Book of Hormones • Founder, Gaya Wellness

Published July 28, 2025 • Updated May 3, 2026

If you are asking about HRT over 70, the most important question is not “Are hormones good or bad?” The better question is, “Are we continuing a useful treatment that started earlier, or are we starting systemic hormone therapy for the first time after decades of menopause?”

Those are not the same clinical situation. A 71-year-old woman who began a low-dose estradiol patch at 52, has no bleeding, normal blood pressure, current breast screening, and severe symptoms every time she tapers is different from a 74-year-old woman with no prior hormone exposure, coronary artery disease, diabetes, migraine with aura, and a new desire to start estrogen for “anti-aging.”

Women deserve better than two lazy answers: “never after 70” and “everyone should be on hormones.” Both skip the work. The real conversation weighs symptom burden, time since menopause, route, dose, uterus status, clot risk, heart history, breast history, bone health, cognition, and the reason treatment is being considered.

Continuation After 70 Versus New Initiation

This distinction is the center of the decision. Continuing HRT after 70 may be reasonable for selected women when the therapy still has a clear indication, the dose is conservative, the route is appropriate, and periodic reassessment is happening. It is not an automatic lifetime prescription, but it is also not automatically wrong.

Starting systemic HRT after 70 is different. By then, most women are more than 20 years from menopause. Baseline risk for stroke, blood clots, coronary disease, and dementia is higher than it was at 52. The same medication lands in a different body with a different risk profile.

That is why I slow down when a woman wants to start systemic estrogen for the first time after 70. I want to know whether she is having true hot flashes or night sweats, whether sleep apnea is contributing, whether medications are causing sweating, whether thyroid disease or infection has been ruled out, and whether the symptom is severe enough to justify systemic exposure.

If she is already using HRT, I ask a different set of questions. Why was it started? What happens when she lowers the dose? Has she had any bleeding? Does she still have a uterus? Is she using progesterone appropriately? Is breast screening current? Has blood pressure, cholesterol, A1c, clot history, or heart history changed?

What Benefits Are Realistic After 70?

The most realistic benefit of systemic hormone therapy is relief of vasomotor symptoms: hot flashes and night sweats. Some women continue to have disruptive symptoms well into their 60s and 70s. If those symptoms are severe, they can fracture sleep, concentration, mood, energy, and quality of life.

Sleep matters. But I am careful here: estrogen is not a general sleeping pill. If hot flashes are waking you up, treating them may improve sleep. If you have insomnia from anxiety, alcohol, pain, sleep apnea, restless legs, medication timing, or poor circadian rhythm, systemic HRT may not be the right tool.

Bone health is another possible benefit. Estrogen prevents bone loss while it is being used, but after 70 I do not use systemic estrogen as a casual bone plan. We need bone density, fracture history, kidney function, vitamin D status, protein intake, strength training, fall risk, and comparison with osteoporosis medications. Sometimes hormones are part of the discussion. Often, a more bone-specific medication is more appropriate.

Genitourinary symptoms are extremely common after 70: vaginal dryness, burning, tearing, painful sex, urinary urgency, recurrent urinary discomfort, and tissue fragility. Many women call this “aging” because nobody has named it as treatable. In many cases, the better treatment is low-dose vaginal estrogen or another local option, not systemic HRT.

What Risks Matter Most Over 70?

The risks that matter most are the risks you personally carry. Age raises the background rate of many conditions, but age alone is not the whole chart. I review prior blood clot, pulmonary embolism, stroke, heart attack, coronary artery disease, uncontrolled blood pressure, migraine with aura, smoking history, diabetes, liver disease, gallbladder disease, breast cancer history, high-risk breast lesions, family history, and unexplained vaginal bleeding.

The Mayo Clinic explains the timing concern plainly: starting menopause hormone therapy at age 60 or older, or more than 10 years since menopause, increases the risk of serious complications. For a woman over 70, that timing issue has to be taken seriously.

Breast risk depends on formulation and history. Estrogen alone after hysterectomy is not the same as estrogen plus a progestogen in a woman with a uterus. Family history, prior biopsy, mammogram findings, dense breasts, alcohol use, weight, and duration of therapy all belong in the conversation.

Dementia risk is also not a slogan. I do not prescribe systemic HRT after 70 to prevent dementia. Brain health at this age belongs in a broader plan: blood pressure control, exercise, sleep, hearing, metabolic health, medication review, and vascular risk reduction.

If there is postmenopausal bleeding, that has to be evaluated before any systemic estrogen decision. Bleeding after menopause is not something to watch casually. It can be benign, but it must be worked up.

Route, Dose, and Product Quality Change the Tradeoff

When women say “HRT,” I ask what exactly they mean. Oral estrogen, transdermal estradiol patch, gel, spray, vaginal estrogen cream, vaginal tablet, vaginal ring, compounded cream, pellet, progesterone capsule, synthetic progestin, and testosterone are different exposures.

Route matters. Oral estrogen passes through the liver first and can affect clotting proteins, triglycerides, and inflammatory markers. Transdermal estradiol avoids that first-pass liver effect. The American College of Obstetricians and Gynecologists describes systemic and local hormone options and emphasizes an annual decision based on symptoms, risks, and benefits.

Over 70, I generally want the lowest effective dose, the most adjustable route, and the clearest indication. I am cautious with pellets because once they are placed, exposure cannot be quickly adjusted. If a woman develops bleeding, breast tenderness, mood changes, acne, hair changes, high levels, or new risk factors, I want the ability to lower or stop therapy promptly.

If a woman has a uterus and uses systemic estrogen, she usually needs endometrial protection with progesterone or another appropriate strategy. Estrogen without protection can stimulate the uterine lining. If she had a hysterectomy, progesterone may not be required for uterine safety. Surgical history is not a footnote. It changes the prescription.

Vaginal Estrogen Is a Separate Conversation

Many women over 70 do not need systemic HRT. They need treatment for genitourinary syndrome of menopause. That includes dryness, burning, painful intimacy, recurrent urinary symptoms, urgency, and fragile tissue that tears easily.

Low-dose vaginal estrogen is local therapy. It is not the same exposure as pills, patches, gels, or sprays. For many older women, local therapy can be discussed even when systemic hormone therapy is not the right fit. Women with a history of estrogen-sensitive cancer still need coordination with their oncology or gynecology team, but “over 70” alone should not end the conversation.

This is one of the places where fear-based counseling has hurt women. A patient says sex hurts, she keeps getting urinary symptoms, and the answer she receives is “you are too old for estrogen.” That answer may confuse systemic risk with local treatment and ignore pelvic floor therapy, vaginal moisturizers, lubricants, sexual medicine, and careful evaluation.

At Gaya, this may connect to hormone replacement therapy for women, hormonal health, menopause care, and broader postmenopause support. The point is not to force every symptom into systemic estrogen. The point is to choose the right level of treatment.

What the FDA Label Changes Mean

The FDA label conversation has changed, and that matters. In 2026, the FDA approved labeling changes for menopausal hormone therapy products, including removal of certain boxed-warning risk statements related to cardiovascular disease, breast cancer, and probable dementia from a first group of products after review of the scientific literature.

I see that as a move toward more accurate counseling, not as permission to prescribe casually. The old warning language trained many clinicians and patients to fear all hormone therapy equally. That was too blunt. But the opposite message, that every woman should now start hormones at any age, is also too blunt.

The right takeaway is precision. The Women’s Health Initiative changed prescribing for a reason, but its findings were often applied without enough attention to age, timing, formulation, route, and the difference between symptom treatment and chronic disease prevention.

For a woman over 70, I use the FDA update to clear away outdated fear, then return to the actual patient: what are we treating, how severe is it, is this continuation or initiation, and what is the reassessment plan?

How I Build the Decision at Gaya

My framework is practical. First, define the target symptom. Hot flashes, night sweats, insomnia, vaginal pain, urinary symptoms, bone loss, mood swings, low libido, and stubborn weight gain may overlap, but they do not all have the same treatment.

Second, map timing. When was menopause? Was there surgical menopause? Were ovaries removed? Did symptoms begin near menopause or suddenly appear at 73? Sudden sweating, palpitations, fevers, or new bleeding should not be automatically labeled menopause.

Third, review risk. I want blood pressure, lipids, A1c, breast screening, bleeding history, clot history, stroke history, heart history, migraine aura, liver disease, medications, tobacco, alcohol, mobility, and family history. If weight and insulin resistance are part of the story, we may connect hormone work with Weight Loss Concierge or Her Longevity.

Fourth, choose the least excessive tool. Sometimes that is a lower-dose transdermal plan. Sometimes it is local vaginal estrogen. Sometimes it is a nonhormonal medication for hot flashes. Sometimes it is sleep evaluation, bone medication, pelvic floor therapy, blood pressure control, thyroid testing, or medication cleanup.

Inside Hormonal Agency™, we do not treat hormones as a trend. We look at symptoms, labs, medical history, uterus status, route, dose, monitoring, and follow-up. We also connect hormone decisions to hot flashes, hormonal imbalance, perimenopause history, and long-term prevention when appropriate.

If you are already on HRT over 70, do not panic and stop without a plan unless your clinician gives you an urgent safety reason. Ask for a real review. If you want to start systemic HRT after 70, expect a more careful process. That caution is not dismissal. It is the respect your body deserves.

The goal is not to win an argument about hormones. The goal is to build a plan that tells the truth about benefit, risk, and your actual life.

Dr. Shweta Patel, MD, FACOG

Board-certified OB/GYN, U.S. Navy veteran, and founder of Gaya Wellness. Dr. Patel leads physician-managed programs in hormone optimization, menopause hormone therapy, and longevity medicine for women in midlife and beyond.

You have not failed. Your plan did.